When treating platinum-sensitive relapse ovarian cancer cells with germline BRCA1/2 mutations, Fluzoparib also exhibited good safety and antitumor activity profiles (Li et al., 2021). This evidence concerns the gene BRCA1 and ovarian carcinoma.